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Abstract
Aims/hypothesis The commonmuscle-specific TBC1D4 p.Arg684Ter loss-of-function variant defines a subtype of non-autoimmune
diabetes in Arctic populations. Homozygous carriers are characterised by elevated postprandial glucose and insulin levels. Because
3.8% of the Greenlandic population are homozygous carriers, it is important to explore possibilities for precision medicine. We aimed
to investigate whether physical activity attenuates the effect of this variant on 2 h plasma glucose levels after an oral glucose load.
Methods In a Greenlandic population cohort (n = 2655), 2 h plasma glucose levels were obtained after an OGTT, physical
activity was estimated as physical activity energy expenditure and TBC1D4 genotype was determined. We performed TBC1D4–
physical activity interaction analysis, applying a linear mixed model to correct for genetic admixture and relatedness.
Results Physical activity was inversely associated with 2 h plasma glucose levels (β[main effect of physical activity] −0.0033
[mmol/l] / [kJ kg−1 day−1], p = 6.5 × 10−5), and significantly more so among homozygous carriers of the TBC1D4 risk variant
compared with heterozygous carriers and non-carriers (β[interaction] −0.015 [mmol/l] / [kJ kg−1 day−1], p = 0.0085). The
estimated effect size suggests that 1 h of vigorous physical activity per day (compared with resting) reduces 2 h plasma glucose
levels by an additional ~0.7 mmol/l in homozygous carriers of the risk variant.
Conclusions/interpretation Physical activity improves glucose homeostasis particularly in homozygous TBC1D4 risk variant
carriers via a skeletal muscle TBC1 domain family member 4-independent pathway. This provides a rationale to implement
physical activity as lifestyle precision medicine in Arctic populations.
Data repository The Greenlandic Cardio-Metabochip data for the Inuit Health in Transition study has been deposited at the European
Genome-phenome Archive (https://www.ebi.ac.uk/ega/dacs/EGAC00001000736) under accession EGAD00010001428.
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Introduction
Type 2 diabetes is a growing global health problem and its
prevalence is also rapidly increasing in Greenland and in other
Arctic populations [1–3]. Recently, a common TBC1D4
p.Arg684Ter loss-of-function variant that defines a specific
subtype of non-autoimmune diabetes characterised by elevat-
ed postprandial glucose levels has been described. The variant
was identified initially in the Greenlandic population (minor
allele frequency of 17%, and 3.8% are homozygous carriers)
and later described in the North American Inuit population
with similar allele frequency [4, 5]. Homozygous carriers are
characterised by postprandial hyperglycaemia (on average
these individuals had 3.8 mmol/l higher 2 h plasma glucose
during an OGTT), impaired glucose tolerance and 10.3-fold
increased odds of developing type 2 diabetes [4]. The muta-
tion is estimated to account for more than 10% of all cases of
type 2 diabetes in Greenland and other Artic Inuit populations
[4, 5]. Based on the variant’s high frequency and the clinical
characterisation of homozygous TBC1D4 risk variant carriers,
it has been suggested that diagnostic strategies for type 2
diabetes should include 2 h OGTT and/or TBC1D4 genotype
risk stratification in Arctic populations [5–7].
There is a plausible pathophysiological explanation for the
observed clinical characteristics of homozygous TBC1D4 risk
variant carriers. TBC1D4 encodes a Rab-GTPase-activating
protein (RabGAP) that represents a key factor in the insulin-
stimulated GLUT4 translocation process [8]. Previously, we
observed decreased GLUT4 content in skeletal muscle of
homozygous carriers and speculate that this likely contributes
to postprandial hyperglycaemia via a possible lowered
glucose uptake in skeletal muscle [4]. Experiments in mice
have shown that knocking down Tbc1d4 causes a decrease
in basal plasma glucose and a decrease in insulin-stimulated
glucose uptake in muscle and adipose tissue [9]. Regular exer-
cise training has been shown to regulate the phosphorylation
of TBC1 domain family member 4 (TBC1D4) in skeletal
muscle from individuals with type 2 diabetes, indicating a role
for RabGAP in the insulin-sensitising effects of exercise train-
ing [10]. Importantly, regular physical activity is widely
accepted as a useful means for both the prevention and treat-
ment of metabolic diseases [11, 12] but the underlying mech-
anisms of the beneficial impact of physical activity on meta-
bolic health are not yet fully understood.
It is not currently known whether daily physical activity
especially benefits indigenous Arctic individuals with a
muscular TBC1D4 deficiency. Such knowledge might
provide a powerful treatment option to effectively lower
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postprandial glucose levels and prevent type 2 diabetes in
these populations and might provide insights into molecular
mechanisms. Motivated by this, our main aim was to estimate
the effect of daily physical activity on the association between
the common TBC1D4 p.Arg684Ter loss-of-function variant
and postprandial plasma glucose levels during a 2 h OGTT
in Greenlandic individuals. As secondary outcomes, we also
examined whether daily physical activity reduces the odds of
developing type 2 diabetes and has beneficial effects on other
cardiometabolic traits in homozygous carriers of this loss-of-
function variant. To our knowledge, this is the first study
investigating the effect of gene–lifestyle interactions on
cardiometabolic traits in Artic populations.
Methods
Study population The Greenlandic cohort (n = 3115), also
known as the Inuit Health in Transition study, is a
population-based study of around 9% of the adult
Greenlandic population. Data was collected after inviting a
random sample of adults aged ≥18 years to participate in the
population health survey in Greenland in 2005–2010.
Pregnant women were not enrolled. Details about the health
survey and data collection method are described in detail else-
where [2]. Prior to participation, informed consent was obtain-
ed from all individuals included into the study. The study was
approved by the Commission for Scientific Research in
Greenland (project 2011-13, ref. no. 2011-056978, and
project 2013-13, ref.no. 2013-090702) and was conducted in
accordance with the principles of the Declaration of Helsinki.
Cardiometabolic traits and definition of type 2 diabetes All
participants without known diabetes (at time of the examina-
tion) underwent a standardised 75 g, 2 h OGTT after an over-
night fast of at least 8 h. Plasma glucose was analysed with the
Hitachi 912 system (Roche Diagnostics). Measurements of
secondary tested cardiometabolic traits are described in the
electronic supplementary material (ESM) Methods. Type 2
diabetes was classified according to WHO criteria [13].
Physical activity assessment Information on daily physical
activity was collected using an interviewer-administrated
version of the International Physical Activity Questionnaire
(long version) that was modified and adapted to Arctic living
conditions (n = 3004 individuals of the entire cohort) as
described in ESMMethods. Physical activity energy expendi-
ture was calculated [14]. This questionnaire was found to be a
valid measure for overall physical activity energy expenditure
among adult Inuit in Greenland [14]. We based our primary
main analysis on questionnaire-derived physical activity for
enhanced power of our statistical analysis since this allowed
us to include as many individuals as possible with valid
information on physical activity, TBC1D4 p.Arg684Ter geno-
type and 2 h plasma glucose concentrations (n = 2655). We
performed sensitivity analysis in a subset of individuals (n =
1388) where physical activity energy expenditure was also
assessed objectively by combined heart rate and acceleration
monitors (ActiHeart; CamNTech, Cambridge, UK) to evalu-
ate whether magnitude and direction of interaction effects
were comparable between subjectively and objectively
assessed physical activity. We included individuals with a
monitor wear time of at least 48 h (n = 1544 individuals in
the entire cohort) for this sensitivity analysis. Due to study
logistics, limited time at each study location and a finite stock
of monitors, not all participants were given an ActiHeart
monitor and the length of recordings from some participants
was shorter [14, 15]. A full description of the population-
specific calibration of the heart rate–energy equation and
assessment of physical activity energy expenditure is docu-
mented elsewhere [14–16]. We translated the effect sizes
derived from the interaction models (β[interaction]) into
aspects of intensity and type of activity to ensure relevance
in the Greenlandic cohort. For this, we derived metabolic
equivalent task (MET) activities based on the definition by
Ainsworth et al [17] and the assumption that an increase in
physical activity energy expenditure of 10 kJ kg−1 day−1 is
equivalent to about 1 h intensity of 3.5 MET per day (e.g.
moderate-pacedwalking at 2.8–3.2 miles per hour whenwalk-
ing for transportation on a firm surface) compared with spend-
ing this hour at rest. We also derived the equivalent to a high-
intensity activity of 9.5MET per day commonly performed by
Greenlanders, namely hiking with hunting gear, compared
with spending this hour at rest [17].
Genotyping Participants from the Greenlandic cohort (n =
3115) were genotyped by the Cardio-Metabochip, a custom
iSelect genotyping array of 196,725 SNPs for genetic studies
of metabolic, cardiovascular and anthropometric traits [18], on
the Illumina HiScan platform (Illumina, San Diego, CA,
USA). Genotypes were called using the GenCall module
(version 1.9.4) of GenomeStudio software (version 2011.1;
Illumina). During quality control using PLINK software tools
(version 1.9; https://www.cog-genomics.org/plink/) [19] we
removed a few individuals with mislabelled sex and high
rate of missing data (>2% of all SNPs with a minor allele
frequency >0.01), leaving 3074 individuals for which array
genotyping was successful accomplished. The p.Arg684Ter
nonsense polymorphism in TBC1D4, rs61736969, was
genotyped in all participants (n = 3040) by applying the
KASP genotyping assay (LGC Genomics, UK).
Statistical analysis Overall, 2655 individuals had complete
information on questionnaire-derived physical activity,
TBC1D4 p.Arg684Ter genotype and 2 h plasma glucose
levels, and hence were included in our primary analysis
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(ESM Fig. 1). We tested for a gene–environment interaction
effect between TBC1D4 p.Arg684Ter genotype and physical
activity on 2 h plasma glucose using a linear mixed model
implemented in GMMAT (version 1.0.3) [20]. We used a
linear mixed model to correct for admixture and relatedness
(see Eq. 1 in ESMMethods). We applied a gene–environment
model with 2 h plasma glucose as response, with main effect
terms for physical activity and TBC1D4 p.Arg684Ter geno-
type, and an additional effect term for interaction between
physical activity and TBC1D4 p.Arg684Ter. Our group has
shown previously that the effect of the TBC1D4 p.Arg684Ter
risk variant on 2 h plasma glucose levels is almost entirely
recessive but there is some effect of being heterozygous [4]. In
the primary analytical model, we therefore modelled the
TBC1D4 p.Arg684Ter effects as recessive. Including the
interaction effect term in the model allowed us to test if the
effect of physical activity is different for homozygous
TBC1D4 p.Arg684Ter risk variant carriers compared with
heterozygous carriers and non-carriers and allowed us to esti-
mate the size of this difference (β[interaction]).
Quantitative traits were transformed using sex-specific rank-
based inverse normal transformations to ensure that they follow a
normal distribution as assumed in the applied model. SEs, effect
sizes (in SD) and p values are reported from transformed analy-
ses. We also report effect sizes from analyses of untransformed
traits. We applied the Wald test implemented in GMMAT [20]
for our primary analysis (see Eq. 1 in ESMMethods), assuming a
significance level of 0.05. We also explored interaction analyses
of TBC1D4 with physical activity on additional cardiometabolic
traits, assuming a significance level of 0.05 (applying Eq. 1,
ESMMethods). Furthermore, we tested for a TBC1D4–physical
activity interaction on type 2 diabetes using a logistic model
implemented in GMMAT (ESM Methods) [20]. We excluded
individuals with known diabetes at the date of examination from
all analyses and individuals taking lipid-lowering medications
were removed in analysis of lipid measures.
Finally, to compare values of 2 h plasma glucose levels for
different physical activity levels for non-carriers, heterozygous
carriers and homozygous carriers of the TBC1D4 p.Arg684Ter
risk variant, we predicted values for each of the three possible
genotypes for a range of physical activity levels. For this, we
used the primary analytical model with the effect sizes estimat-
ed based on untransformed 2 h plasma glucose levels. To obtain
predictions relative to an average non-carrier individual with a
physical activity level of 50 kJ kg−1 day−1, we subtracted
50 kJ kg−1 day−1 multiplied by β1 (β[main effect for physical
activity]) from all predicted values.
Results
Clinical characteristics of the Greenlandic individuals includ-
ed in the presented analyses are shown in ESM Table 1. We
found that homozygous TBC1D4 p.Arg684Ter variant
carriers had highly elevated levels of 2 h plasma glucose
compared with non-carriers (β[main effect of being homozy-
gous TBC1D4 risk variant carrier] = 4.2 mmol/l, p = 1.2 ×
10−40, n = 2655), which is consistent with our previous obser-
vation [4]. Furthermore, physical activity was inversely asso-
ciated with 2 h plasma glucose levels (β[main effect of phys-
ical activity] = −0.0033 [mmol/l] / [kJ kg−1 day−1], p = 6.5 ×
10−5, n = 2655, Fig. 1a).
The effect of physical activity on 2 h plasma glucose levels
was significantly greater among homozygous carriers of the
TBC1D4 variant compared with heterozygous carriers and
non-carr iers (β [ in terac t ion] = −0.015 [mmol/ l ] /
[kJ kg−1 day−1], p = 0.0085, n = 2655; Fig. 1b, Table 1 and
ESM Fig. 2a). Additional adjustment for BMI did not change
the magnitude of interaction (β[interaction] = −0.015
[mmol/l] / [kJ kg−1 day−1] , p = 0.011, n = 2635).
Importantly, we confirmed the magnitude and direction of
the interaction effect in the subset of individuals with available
information on objectively assessed physical activity
(β[interaction] = −0.024 [mmol/l] / [kJ kg−1 day−1], p = 0.45,
n = 1388; Table 1). We did not find any significant difference
in physical activity energy expenditure when comparing
homozygous TBC1D4 p.Arg684Ter carriers, heterozygous
carriers and non-carriers in the Greenlandic population (p =
0.65). Additional adjustment of the primary analytical model
for total energy consumption did not change the magnitude of
β(interaction) in individuals with available information on
total energy consumption (data not shown).
To be clinically useful, it is important to translate the effect
sizes derived from the interaction models (β[interaction]) into
real-life settings. Our results suggest that for every
10 kJ kg−1 day−1 increase in physical activity energy expen-
diture, concentrations of 2 h plasma glucose were reduced by
an additional ~0.2 mmol/l in homozygous TBC1D4
p.Arg684Ter carriers compared with heterozygous carriers
and non-carriers (Table 1). This difference in physical activity
corresponds to about 1 h of activity at an intensity of 3.5 MET
per day (e.g. moderate-paced walking) compared with spend-
ing this hour at rest [17]). More extremely, 1 h daily of a high-
intensity activity commonly performed by Greenlanders (e.g.
hiking with hunting gear), compared with spending this hour
at rest [17], decreased 2 h plasma glucose levels by an addi-
t ional ~0.4–0.7 mmol/ l in homozygous TBC1D4
p.Arg684Ter carriers compared with heterozygous carriers
and non-carriers (based on self-reported and objective
assessed physical activity, respectively; Table 1).
We also investigated the effect of the TBC1D4
p.Arg684Ter–physical activity interaction on 2 h plasma
glucose levels under a standard additive interaction model
(ESM Methods) and found similar or stronger interaction
effects compared with the applied primary recessive interac-
tion model. Remarkably, the additive model showed a
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significant interaction effect in the sensitivity analysis of the
subset including individuals with objectively measured physi-
cal activity (p = 0.027, Table 1). To ensure that the results of our
primary analysis were not confounded by admixture, we strat-
ified individuals included into the analysis by different degrees
of European admixture (0–5%, 5–20%, 20–35% and >35%
European admixture) and performed interaction analysis by
applying the primary model to each subgroup separately.
None of the interaction effects for the different admixture
groups was significantly in the opposite direction, when taking
the uncertainty of the estimates into account, indicating that the
presented results are not confounded by population structure
(ESM Fig. 2b). Furthermore, we did not observe inflation of
our test statistic (λ = 0.82, ESM Fig. 2c), confirming that the
applied linear mixed model satisfactorily accounts for admix-
ture and relatedness among the included individuals.
While our primary aim was to investigate the effect of the
TBC1D4–physical activity interaction on 2 h plasma glucose,
our second aim was to investigate the effect of the interaction
on the probability of having type 2 diabetes. We included 240
individuals with type 2 diabetes (of these, 38 individuals were
homozygous TBC1D4 p.Arg684Ter variant carriers) and
1969 individuals with normal glucose tolerance as a control
group (of these, 28 individuals were homozygous TBC1D4
p.Arg684Ter variant carriers) in a logistic model. We found
indication of an interaction effect, suggesting an attenuation in
the association between the TBC1D4 p.Arg684Ter risk variant
and odds of type 2 diabetes per kJ kg−1 day−1 unit increase in
daily physical activity (OR 0.99 [95% CI 0.97, 1.00], p =
0.11)]. To put this into context, the probability of having type
2 diabetes for a standard individual (40-year-old, male sex)
who was a homozygous TBC1D4 risk variant carrier and had
an assumed physical activity energy expenditure of
50 kJ kg−1 day−1 (approximate median of the cohort) was
0.44. Notably, the probability for type 2 diabetes was reduced
to 0.40 with an additional 1 h of moderate activity
(60 kJ kg−1 day−1) and it was reduced to 0.35 with an addi-
tional 1 h of vigorous activity (77 kJ kg−1 day−1) per day
(ESM Fig. 3a). We did not observe inflation of test statistic
in the analysis based on the logistic model (λ = 1.11, ESMFig.
3b).
Lastly, we investigated the effect of the TBC1D4–physical
activity interaction on other cardiometabolic traits and found
nominal ly signi f icant effec ts on wais t /h ip ra t io
(β[interaction] = −0.00026 / [kJ kg−1 day−1], p = 0.047, n =
2872; ESM Table 2) and insulin sensitivity index
(β[interaction] = 0.0024 / [kJ kg−1 day−1], p = 0.045, n =
2634; ESM Table 2).
Discussion
In the present study of the Greenlandic population, we found
that homozygous carriers of the common muscle-specific
TBC1D4 p.Arg684Ter loss-of-function variant benefit from
physical activity, as shown by lower postprandial plasma
Fig. 1 Physical activity attenuates the effect of the common muscle-
specific TBC1D4 p.Arg684Ter loss-of-function variant on 2 h plasma
glucose levels in 2655 Greenlanders. (a) Raw data points (physical activ-
ity measured as physical activity energy expenditure on the x-axis and 2 h
plasma glucose levels on the y-axis) stratified by TBC1D4 p.Arg684Ter
genotype. (b) Illustration of the TBC1D4–physical activity interaction
effect on 2 h plasma glucose levels relative to a standard individual in
Greenlanders. For each individual, the respective mean physical activity
energy expenditure per day is plotted on the x-axis. The y-axis displays
the difference in 2 h plasma glucose levels for each individual compared
with a standard individual (defined as non-carrier having an assumed
physical activity energy expenditure of 50 kJ kg−1 day−1 [~ median of
the cohort, illustrated by the black circle]). The predictions were
performed using the estimated effect sizes from the primary analytical
model and 95% CIs are shown. HE, heterozygous TBC1D4 p.Arg684Ter
variant carriers; HO, homozygous TBC1D4 p.Arg684Ter variant carriers;
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glucose levels after an oral glucose load and reduced proba-
bility for developing type 2 diabetes. We also found that the
effect of physical activity is markedly greater for these
carriers.
In fact, the effect size of the gene–environment interaction
between the common TBC1D4 p.Arg684Ter loss-of-function
variant and physical activity on 2 h plasma glucose levels in
Greenlanders is remarkably large compared with previously
identified gene–environment interactions for complex human
traits [21–23]. Previous studies in individuals of European
ancestry have examined interactions of type 2 diabetes-
associated genetic variants and physical activity on metabolic
disease traits with mixed results [24–26]. Here, we report that
1 h ofmoderate-paced walking or 1 h of high-intensity activity
lowers 2 h plasma glucose levels by an additional ~0.2 mmol/l
and up to ~0.7 mmol/l, respectively, compared with spending
this hour at rest. To place our observed effect sizes of the
TBC1D4–physical activity interaction on 2 h plasma glucose
levels in Greenlandic individuals into context, we looked up
the reported effect of lifestyle intervention on 2 h plasma
glucose levels in previously conducted landmark studies.
Specifically, the results of the Finish Diabetes Prevention
Study showed that 1 year of intensive lifestyle intervention,
including 30 min of moderate physical activity per day, diet
changes and reduction of body weight, reduced 2 h plasma
glucose levels by ~0.6 mmol/l more in the intervention group
compared with the control group [11]. After 3 years of inten-
sive lifestyle intervention, the difference in 2 h plasma glucose
levels between the intervention group and the control group
was reduced to ~0.4 mmol/l [11]. Remarkably, we derived a
similar effect size for isolated habitual physical activity in an
epidemiological setting. The large effect size of the TBC1D4–
physical activity interaction on 2 h plasma glucose and the
high frequency of the TBC1D4 p.Arg684Ter loss-of-
function variant in the indigenous Arctic population enables
a direct translation of the benefit of physical activity to tailored
reduction of postprandial glucose levels for a substantial part
of the population (i.e. the homozygous variant carriers).
We found indication that physical activity may have a
greater beneficial effect on some (i.e. type 2 diabetes, waist/
hip ratio and insulin sensitivity index) but not all of the tested
secondary outcomes in homozygous TBC1D4 p.Arg684Ter
loss-of-function carriers, compared with heterozygous carriers
and non-carriers. However, the results relating to secondary
outcomes need to be interpreted with caution since we present
results without adjustment for multiple testing. Long-term
follow-up is needed before being able to make conclusions
on whether there is increased risk for CVD among TBC1D4
risk variant carriers and whether physical activity may have
beneficial effects on other cardiometabolic risk traits.
The discovery of gene–physical activity interactions on
diabetes outcomes is challenging in commonly studied popu-
lations (such as European and Asian) and requires large
sample sizes, acquired through large research biobanks or
large-scale multicentre meta-analysis, that often exceed the
sample size needed to identify main effects of genetic variants
[21]. Therefore, our results add to the growing literature on
genetic analysis in population isolates, such as the
Greenlandic Inuit population. Such studies can provide a
powerful approach to identify genetic variants, identify
gene–environment interactions with clinical relevance, and
gain knowledge into the molecular mechanisms of common
disease traits [27].
Our finding of the physical activity-induced reduction of
postprandial glucose levels in quasi muscle-specific human
knockouts carrying the TBC1D4 p.Arg684Ter variant may
pave the way towards new insights into molecular mecha-
nisms. The variant confers loss of expression of a long
TBC1D4 isoform in skeletal muscle, while other insulin-
sensitive tissues display normal expression of a short
TBC1D4 isoform [4]. As a consequence, skeletal muscle
expression levels of the long TBC1D4 isoform mRNA and
protein are decreased with increasing number of TBC1D4
p.Arg684Ter risk alleles, with homozygous carriers having
practically no expression [4]. Our previous study of the human
homozygous TBC1D4 p.Arg684Ter variant carriers [4] and
studies in Tbc1d4-knockout mice unequivocally suggest that
lack of TBC1D4 lowers total GLUT4 protein content in
specific muscle fibre types [28–31]. In addition, insulin-
stimulated translocation of the GLUT4 transporter proteins
to the plasma membrane might be compromised, albeit not
to the same extent in different muscle fibre types [31]. The
combination of lowered GLUT4 content and compromised
insulin-stimulated GLUT4 translocation is suggested to lead
to the postprandial hyperglycaemia and hyperinsulinaemia
observed in the human homozygous TBC1D4 p.Arg684Ter
variant carriers [4, 5].We speculate that the benefit of physical
activity on lowering postprandial glucose levels in homozy-
gous muscle-specific TBC1D4 p.Arg684Ter loss-of-function
carriers might be mediated via a TBC1D4-independent
muscle-specific pathway and/or tissue crosstalk from muscle
to other tissues that do have an intact TBC1D4 signalling
pathway. One recent example of a study pointing towards
inter-organ crosstalk showed that exercise training improves
glucose tolerance through crosstalk between muscle and
adipose tissue through an exercise-induced adipokine [32]. It
may also be possible that a change in TBC1D1, which has also
been implicated in contraction induced glucose uptake [33,
34], may contribute to the enhanced response to physical
act ivi ty in homozygous carr iers of the TBC1D4
p.Arg684Ter loss-of-function variant.
We performed several sensitivity analyses that strengthen
our findings. In the subset of individuals for whom we had
information on objectively assessed physical activity we
confirmed the direction and magnitude of the interaction
effect. The lack of statistical significance in this sensitivity
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analysis is clearly a power issue, considering the loss, overall,
of 1267 individuals (including 53 homozygous TBC1D4
p.Arg684Ter variant carriers) compared with the analysis based
on questionnaire-derived physical activity. Interestingly, the
commonly used additive model showed that the TBC1D4
p.Arg684Ter–physical activity interaction also had a significant
effect on 2 h plasma glucose levels in the subset of individuals
with objectively assessed physical activity. However, the
magnitude of the interaction effect was overall smaller than
the interaction effect derived from the primary model, likely
due to heterozygous TBC1D4 p.Arg684Ter variant carriers that
are accounted for in an additive interaction model but not in the
primary recessive model. Compared with homozygous carriers,
in heterozygous carriers (more common in the Greenlandic
population [4]) the TBC1D4 p.Arg684Ter variant has less of
an effect on metabolic traits, explaining the increased statistical
power by applying an additive interaction model. Finally, the
presented results are not confounded by population structure,
the degree of admixture or relatedness among the Greenlandic
population.
We were limited to the analysis of epidemiological data
collected as part of a general health survey of the
Greenlandic population and therefore the reported effect sizes
need careful interpretation. To quantify the clinical impact of
physical activity in carriers of the TBC1D4 p.Arg684Ter loss-
of-function variant and, based on this, recommend
personalised treatment, an exercise-training intervention trial
specifically targeted to Arctic individuals should be
performed. Such a trial might include detailed OGTT
measures of glucose homeostasis and type 2 diabetes remis-
sion as primary outcomes, as well as collection of tissue biop-
sies for functional and biochemical analysis. If designed prop-
erly, studies of human TBC1D4 p.Arg684Ter loss-of-function
variant carriers may also provide information on molecular
mechanisms of the role of TBC1D4 in the beneficial effects
of physical activity and determine whether TBC1D1may play
a contributary role in the enhanced response to physical activ-
ity in homozygous carriers of the TBC1D4 p.Arg684Ter loss-
of-function variant. We measured circulating glucose levels
during an OGTT and interpreted our results as if skeletal
muscle is the major tissue involved in exercise-induced prim-
ing of glucose uptake. However, we cannot exclude that other
organs such as adipose tissue may play a role in the improved
glucose tolerance in homozygous TBC1D4 variant carriers
who spend more time performing physical activity.
In summary, the results of our study suggest that regular
moderate physical activity produces a clinically relevant
improvement in postprandial glucose levels in indigenous
Arctic individuals carrying two copies of the TBC1D4
p.Arg684Ter loss-of-function variant. This provides a ratio-
nale to implement lifestyle intervention therapy by motivating
a physically active lifestyle among homozygous carriers of
this variant, constituting 3.8% of the population.
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